CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 4 enrolled
Drug / intervention
Avacincaptad Pegoldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02397954
NCT02397954Phase 2Completed
CompareCT.gov

A Phase 2a Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)

Ophthotech Corporation·interventional·Posted Mar 25, 2015·Updated Mar 20, 2025

In Brief

A Phase 2 clinical trial evaluating Avacincaptad Pegol for Idiopathic Polypoidal Choroidal Vasculopathy. Completed, enrolled 4 participants across 1 site.

Detailed Summary

The objectives of this study are to evaluate the safety and tolerability of Zimura™ intravitreous injection in combination with anti-vascular endothelial growth factor (VEGF) therapy in subjects with Idiopathic Polypoidal Choroidal Vasculopathy (IPCV).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIdiopathic Polypoidal Choroidal Vasculopathy
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 25, 2015
Enrollment StartMar 12, 2015
Primary CompletionOct 23, 2015
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 11.3 years ago

Interventions

Avacincaptad Pegoldrug

Subjects will receive monthly intravitreous injections of Avacincaptad Pegol in combination with Lucentis, Avastin or Eylea.